US Patent 8,906,898: Ceftolozane Sulfate Form 2 Claims, Expiration, Orange Book Status, and Patent Landscape

US Patent 8,906,898 protects ceftolozane sulfate Form 2 through a combination of crystal-form fingerprints, pharmaceutical compositions, lyophilized products, manufacturing conditions, and ceftolozane-tazobactam combinations. The patent is commercially important because its claims map closely to the injectable Zerbaxa product, which contains ceftolozane sulfate and tazobactam sodium. The patent was issued to Cubist Pharmaceuticals, later acquired by Merck, and has a projected term extending into 2032, subject to patent-term adjustment and any terminal disclaimer recorded in the patent file.[1]

The strongest claims are claims 1, 6, 13, and 17. Claims 1 and 6 cover the Form 2 solid material and compositions containing it. Claims 13 and 17 extend protection to lyophilized ceftolozane products made from Form 2. Claims 15 through 29 specifically reach ceftolozane-tazobactam products, including the commercial 1,000 mg/500 mg dosage configuration.

What does US Patent 8,906,898 protect?

US 8,906,898 protects four related subject-matter categories:

Claim category	Principal claims	Protected subject matter
Solid form	1-5	Ceftolozane sulfate Form 2 identified by XRPD, Raman, DSC, and TGA characteristics
Pharmaceutical composition	6-12	Form 2 in a composition, including excipients and, in some claims, another ceftolozane sulfate form
Lyophilized ceftolozane	13-14	A freeze-dried product made by dissolving Form 2 with water, sodium chloride, and L-arginine
Ceftolozane-tazobactam products	15-30	Lyophilized or combined products containing tazobactam, including tazobactam sodium and the 1,000 mg/500 mg ratio

The patent does not claim ceftolozane as a broad chemical entity. Its principal limitation is the physical form of ceftolozane sulfate and the use of that form in injectable pharmaceutical products.

What is the scope of independent claim 1?

Claim 1 covers ceftolozane sulfate Form 2 identified by five XRPD reflections:

XRPD peak	Permitted range under claim
4.4° 2θ	4.2° to 4.6°
8.8° 2θ	8.6° to 9.0°
11.0° 2θ	10.8° to 11.2°
14.9° 2θ	14.7° to 15.1°
17.7° 2θ	17.5° to 17.9°

The claim is a product claim, not merely a process claim. A competing manufacturer would face risk if its isolated ceftolozane sulfate material exhibits the claimed diffraction pattern, regardless of whether it used the same crystallization process.

The XRPD limitation is central. The other analytical characteristics in claims 2 through 5 provide narrower fallback positions but are not required by claim 1.

How do claims 2 through 5 narrow Form 2 protection?

Claims 2 through 5 add orthogonal analytical fingerprints:

Raman shifts at approximately 151, 684, and 802 cm⁻¹.
A DSC endotherm with a minimum at approximately 105°C.
TGA weight loss of approximately 6.8% between 25°C and 181°C.
A combined Raman profile including peaks at approximately 151, 684, 802, 1174, and 2953 cm⁻¹.

These limitations may help distinguish Form 2 from other ceftolozane sulfate forms during litigation or regulatory review. They also create potential claim-construction disputes because terms such as “about,” “approximately,” and analytical tolerances can depend on instrument calibration, sample preparation, heating rate, humidity, and testing protocol.

What pharmaceutical compositions are protected?

Claim 6 covers a pharmaceutical composition containing ceftolozane sulfate Form 2. Claim 6 does not require tazobactam. Claims 9 and 15 through 30 add tazobactam-related limitations.

The composition claims cover products containing:

Form 2 ceftolozane sulfate;
Sodium chloride;
L-arginine;
Citric acid;
Tazobactam;
Tazobactam sodium;
Crystalline tazobactam;
A pharmaceutically acceptable excipient;
A beta-lactamase inhibitor compound.

Claims 8 and 12 have unusual breadth in a different direction. Claim 8 covers a composition containing both Form 2 and another ceftolozane sulfate form identified by XRPD reflections at 12.4, 16.4, 22.6, 25.1, and 28.0° 2θ. This creates a potential overlap zone for products containing polymorphic mixtures or material that partially converts between forms.

What lyophilized products are covered by the patent?

Claims 13 and 17 cover lyophilized ceftolozane compositions produced by:

Combining Form 2 ceftolozane sulfate with water;
In some claims, adding sodium chloride and L-arginine;
Forming an aqueous solution;
Lyophilizing the solution.

The claims cover lyophilization with or without tazobactam. Claims 18 and 19 specifically cover tazobactam or tazobactam sodium in the aqueous solution. Claims 20 and 26 allow the ceftolozane product to be lyophilized separately and combined later with tazobactam.

This structure is commercially relevant because Zerbaxa is supplied as a sterile powder for intravenous infusion and is reconstituted before administration.[2]

What manufacturing conditions are claimed?

Claims 14 and 29 recite process parameters that may be relevant to manufacturing-scale infringement:

Process limitation	Claimed parameter
Ceftolozane concentration	Not more than 150 mg free base per gram of bulk solution
Fill depth	No more than 3 cm
Freezing temperature	At least −40°C
Drying temperature	No more than 40°C
Primary-drying pressure	Not more than 400 µbar at the start of primary drying

These limitations may be difficult to assess from the finished vial alone. A patent owner would typically need batch records, manufacturing testimony, process-development records, discovery of regulatory submissions, or testing capable of reconstructing whether the accused product was made using the claimed conditions.

Because claims 13 and 17 are written as compositions “obtained by” a process, infringement analysis may raise product-by-process issues. Under US patent law, a product-by-process claim generally requires the claimed product characteristics and does not automatically make every process step independently enforceable against a separately made product.[3]

How do the claims cover the 1,000 mg ceftolozane and 500 mg tazobactam product?

Claims 16, 22, 23, 25, and 26 specifically address the commercial fixed-dose ratio:

Approximately 1,000 mg ceftolozane active;
Approximately 500 mg tazobactam active;
A 2:1 ceftolozane-to-tazobactam active ratio.

The claims are directed to active amounts rather than simply the mass of the corresponding sulfate or sodium salt. That distinction matters because the formulation may contain more than 1,000 mg of ceftolozane sulfate by weight while delivering approximately 1,000 mg of ceftolozane active.

The ratio claims are narrower than a general composition claim but commercially significant. A generic or follow-on injectable product matching the Zerbaxa strength and containing Form 2 would face an elevated risk of literal infringement under several overlapping claim paths.

What is the patent expiration date for US 8,906,898?

US 8,906,898 was issued on December 9, 2014. The patent derives from an application claiming priority to earlier ceftolozane sulfate work and has a projected statutory expiration in November 2032, before any applicable patent-term adjustment.[1]

Event	Date
Earliest disclosed priority	November 7, 2011
US filing or national-stage chronology	2012-2014 family period
Patent issued	December 9, 2014
Projected base term	November 2032
Commercial significance	Protection extends well beyond the original 2014 Zerbaxa launch

The earliest provisional filing does not ordinarily determine the 20-year US patent term. The operative term generally runs from the earliest effective nonprovisional or international filing date, subject to patent-term adjustment, terminal disclaimers, and statutory changes. The USPTO Patent Center record controls the final term calculation.[4]

What is the Orange Book status of US 8,906,898?

Zerbaxa is approved by FDA as ceftolozane and tazobactam for injection. The FDA Orange Book and associated product-label patent disclosures identify an active patent estate covering the product’s composition, solid form, formulation, and related pharmaceutical characteristics.[5]

US 8,906,898 is relevant to the Orange Book analysis because its claims cover the Form 2 ceftolozane sulfate and lyophilized compositions used in the approved product. Orange Book listing practice depends on whether a patent claims the drug substance, drug product, or an approved method of use. A solid-form patent may qualify when it claims the active ingredient as used in the approved drug product, but the listing must be assessed against FDA’s patent-listing requirements and the specific Orange Book entry.

The listed estate associated with Zerbaxa includes patents directed to:

Ceftolozane sulfate solid forms;
Pharmaceutical compositions;
Lyophilized injectable products;
Ceftolozane-tazobactam combinations;
Related methods of treatment and product characteristics.

The Orange Book entry should be checked against the current FDA publication because patent listings, delistings, and expiration dates can change over time.[5]

When does Zerbaxa lose exclusivity?

Zerbaxa’s principal commercial exclusivity risk is patent-driven rather than based solely on FDA regulatory exclusivity.

Exclusivity type	Relevance
New chemical entity exclusivity	The original five-year NCE period has expired
Orphan exclusivity	Zerbaxa is not principally protected through orphan exclusivity
Pediatric exclusivity	Any six-month pediatric extension must be confirmed against the FDA record
Patent exclusivity	The key commercial barrier extends into approximately 2032
Generic competition	Most meaningful risk begins after expiry or through successful Paragraph IV litigation

FDA approval alone does not prevent an ANDA applicant from filing a Paragraph IV certification against listed patents. A generic applicant can challenge listed patents before their expiration and seek approval for launch after resolving the patent dispute or prevailing in litigation.

Which companies are challenging Zerbaxa patents?

The cited public patent and FDA sources do not establish a completed Paragraph IV judgment, final settlement, or authorized generic launch involving US 8,906,898. No specific challenger should be treated as commercially cleared solely because an ANDA may exist.

A Paragraph IV case would generally become public through:

A patent-owner complaint filed within 45 days of receiving notice;
A district-court docket;
An FDA litigation-related approval restriction;
A settlement or licensing disclosure;
A later ANDA approval or commercial launch.

The absence of a publicly identified final challenge does not eliminate future risk. The patent’s long remaining term gives generic applicants an incentive to pursue design-around strategies, declaratory-judgment actions, or coordinated challenges against the broader Zerbaxa patent estate.

How strong is the patent estate for ceftolozane and tazobactam?

The estate is strongest where the commercial product uses the exact claimed solid form and manufacturing architecture.

Risk area	Assessment
Form 2 ceftolozane sulfate	High risk if XRPD and analytical data match the claim
Alternative polymorph	Potential design-around, subject to stability and regulatory performance
Lyophilized ceftolozane	High risk where Form 2 and claimed excipients are used
Zerbaxa 1,000/500 mg ratio	High risk under multiple composition claims
Tazobactam-free ceftolozane	Lower risk under claims limited to tazobactam combinations
Different excipient system	May avoid narrower excipient claims but not claim 6 or 17
Different lyophilization cycle	May avoid process limitations but not necessarily product claims
Non-Form 2 solid form	Potentially meaningful design-around if the resulting product remains stable and approvable

The overlapping claim structure improves enforcement resilience. If a challenger avoids the XRPD limitation, claims directed to a different product form may become relevant. If it changes the formulation, claims 1 and 6 may still matter. If it changes the solid form and process, regulatory comparability and product-performance requirements become the practical constraint.

What generic launch scenarios exist?

Launch after patent expiry

This is the lowest litigation-risk path. An ANDA applicant would still need to satisfy FDA requirements for injectable product quality, sterility, stability, bioequivalence, and labeling.

Paragraph IV challenge

A challenger could argue that the Form 2 claims are invalid or not infringed. Likely technical issues include:

Anticipation by an earlier ceftolozane sulfate form;
Obviousness based on polymorph screening;
Inherency of the claimed XRPD pattern;
Indefiniteness of “about” and analytical tolerances;
Lack of written description for the claimed composition and process combinations;
Non-infringement based on a different polymorph or lyophilization process.

Polymorph design-around

A manufacturer could seek a ceftolozane sulfate form with a distinct XRPD pattern. This approach may reduce literal infringement risk but would require its own crystallization, stability, toxicology, and manufacturing package.

Licensed or authorized entry

A settlement could permit entry before patent expiry. No cited source establishes a current license, covenant not to sue, or authorized generic arrangement for US 8,906,898.

What geographic coverage does the patent have?

US 8,906,898 provides protection only in the United States. Related patent-family members may protect corresponding ceftolozane sulfate forms and formulations in Europe, Japan, China, Canada, and other markets, but foreign scope depends on national prosecution and granted claims.

A US non-infringement position does not resolve foreign exposure. The same manufacturer may face different outcomes because:

Patent claims vary by jurisdiction;
Supplementary protection certificates may apply in Europe;
Patent-term adjustments differ;
Regulatory linkage rules vary;
Some countries may have no granted counterpart;
Process and product-by-process claim treatment differs among courts.

What manufacturing and intellectual-property barriers remain after patent expiry?

Patent expiry will not remove all entry barriers. A generic injectable manufacturer must reproduce or independently establish:

Sterile manufacturing controls;
Compatible vial and closure systems;
Reconstitution performance;
Moisture control;
Lyophilized cake integrity;
Stability of ceftolozane and tazobactam;
Impurity specifications;
Container-closure integrity;
Commercial-scale freeze-drying capacity.

Ceftolozane is a beta-lactam antibacterial, and the product’s sterile injectable presentation creates more demanding manufacturing requirements than an oral solid. The patent’s Form 2 claims raise the technical barrier because a manufacturer may need to control polymorphic form, hydration state, residual moisture, and conversion during dissolution and lyophilization.

How does US 8,906,898 compare with broader ceftolozane patents?

US 8,906,898 is narrower than a basic compound patent but closer to the marketed product. A compound patent would protect the ceftolozane molecule across forms and formulations. This patent instead targets the form and product architecture that support the injectable commercial presentation.

Patent type	Scope	Commercial relevance
Compound patent	Broad chemical molecule	Broadest theoretical scope
Solid-form patent	Specific polymorph or hydrate	Strong where the marketed API uses that form
Formulation patent	Excipients, dosage form, concentration	Strong against matching finished products
Lyophilization patent	Product made under specified conditions	Stronger where process records are accessible
Method-of-use patent	Treatment indication or dosing	Relevant to label carve-outs and induced infringement

US 8,906,898 combines solid-form and formulation protection. That combination gives it greater practical relevance to Zerbaxa than a narrowly isolated polymorph claim would have.

Key Takeaways

US 8,906,898 protects ceftolozane sulfate Form 2 through XRPD and additional Raman, DSC, and TGA characteristics.
Claims 6 through 12 cover pharmaceutical compositions containing Form 2.
Claims 13 through 30 cover lyophilized ceftolozane products and ceftolozane-tazobactam combinations.
The 1,000 mg ceftolozane and 500 mg tazobactam configuration is expressly addressed.
The projected patent term extends into approximately November 2032, subject to the USPTO’s final term calculation.
The primary design-around strategy is use of a different ceftolozane sulfate form, but regulatory and manufacturing requirements may limit that option.
No cited source establishes a final Paragraph IV judgment, settlement, or authorized generic launch involving this patent.
The patent is strongest against a product using Form 2, the claimed excipient system, and the commercial 2:1 active-ingredient ratio.

FAQs

Does US 8,906,898 claim ceftolozane itself?

No. The patent claims a specific ceftolozane sulfate solid form and compositions containing that form. It does not function as a broad composition-of-matter patent covering every ceftolozane product.

Can a generic avoid the patent by using ceftolozane free base?

Potentially, but the resulting commercial product would need to satisfy the formulation, stability, sterility, and regulatory requirements for the approved injectable product. Avoiding the sulfate form does not automatically avoid other Zerbaxa-related patents.

Does claim 1 require every listed XRPD peak?

Yes. Claim 1 recites a Form 2 material having diffractions at all five specified angles within the stated ±0.2° 2θ tolerance. Failure to show one required peak may support a non-infringement position, subject to claim construction and analytical proof.

Are claims 13 and 17 process claims or product claims?

They are composition claims defined by how the lyophilized composition is obtained. Their enforceability may depend on both the final product and the legal treatment of the recited preparation steps under product-by-process doctrine.

Can a company sell ceftolozane-tazobactam before 2032?

Only if it avoids valid, enforceable claims, obtains a license or settlement allowing earlier entry, prevails in patent litigation, or relies on another legally available pathway. FDA approval by itself does not eliminate the patent barrier.

References

United States Patent No. 8,906,898. (2014). Ceftolozane sulfate solid forms and pharmaceutical compositions thereof. United States Patent and Trademark Office.
U.S. Food and Drug Administration. (2023). Zerbaxa (ceftolozane and tazobactam) prescribing information. Merck Sharp & Dohme LLC.
U.S. Supreme Court. (2009). Abbott Laboratories v. Sandoz, Inc., 566 F.3d 1282, aff’d in relevant part, 566 F.3d 1281.
United States Patent and Trademark Office. (2024). Patent term adjustment and patent term extension. USPTO.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Cubist Pharms Llc	ZERBAXA	ceftolozane sulfate; tazobactam sodium	POWDER;INTRAVENOUS	206829-001	Dec 19, 2014		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial			Y		⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2014233633	⤷ Start Trial
Australia	2016200570	⤷ Start Trial
European Patent Office	3049079	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,906,898

Which drugs does patent 8,906,898 protect, and when does it expire?

Summary for Patent: 8,906,898